Clinicians should consult literature so treatment options are current

Article

If the diploma on your office wall isn't freshly minted, chances are many of the decisions you make every day are based on outdated information from your optometry school classes.

Atlanta-If the diploma on your office wall isn't freshly minted, chances are many of the decisions you make every day are based on outdated information from your optometry school classes.

"There are a number of things we were taught during our training that, on reflection and further study, we find are no longer true or were never true, but rather based upon opinion and not fact," said Joseph Sowka, OD, FAAO, Diplomate, at the SECO meeting.

Myth: Dilate blood pressure patients

For example, clinicians have long been hesitant to dilate patients with markedly elevated blood pressure, particularly using an agent such as phenylephrine. The fear was that the drug, even at a low concentration of 2.5%, would further elevate blood pressure and put patients at risk of a cardiac event, Dr. Sowka said.

"There's never been any support behind this concept," he added. "When you look in the literature, there have been no adverse effects to patients using this agent at this concentration."

Myth: Dilating pregnant patients

Clinicians are also concerned about dilating patients who are pregnant or nursing. Their unease is due to the fear of teratogenic effects to the unborn child or the possibility of toxicity or other life-threatening effects to the newborn.

"When risks are outweighed by benefits of either dilation or therapeusis, this sometimes needs to be done," Dr. Sowka added. "But it should be done with informed consent from the patient and possibly in consult with the obstetrician."

He said that the highest potential for teratogenicity to the fetus is in the first trimester.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.